ThinkPanmure Initiates Coverage on Vertex (VRTX) with a Source of Funds
More News related to VRTX
- Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
- Merriman Curhan Ford Downgrades Vertex Pharmaceuticals (VRTX) to Neutral; Valuation Call
- Vertex Pharmaceuticals Announces Webcast of its Presentation at the Lazard Capital Markets Annual Healthcare Conference
- Vertex Pharmaceuticals Announces Agreements to Exchange $109.0 Million of its 2013 Convertible Senior Subordinated Notes into Common Stock
- Vertex Pharma (VRTX) January puts spreaders active on low volatility
ThinkPanmure initiates coverage on Vertex Pharmaceuticals (Nasdaq: VRTX) with a Source of Funds. Price target $31.
Vertex Pharmaceuticals Incorporated (Vertex) is a biotechnology company in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases.
Related Categories
New CoverageStocks Mentioned
-0.38Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
